Genetron Holdings Limited (“Genetron Health” or the “Company”,
Nasdaq: GTH), a leading precision oncology platform company that
covers full-cycle cancer care, presented data from 14 clinical
research studies at the American Association for Cancer
Research (AACR) Virtual Annual Meeting II held June 22 to
24. The presented data demonstrated the sensitivity and
specificity of Genetron’s industry-leading next generation
sequencing (NGS) technologies utilized by cancer hospitals to
detect genetic alterations for clinical management.
Data presented at the AACR Virtual Annual
Meeting were generated in collaboration with more than 10
well-known cancer research institutions and hospitals in China.
Genetron’s innovative technologies, including library construction
and enrichment, unknown gene fusion detection, and liquid biopsy
testing, were featured in 14 clinical studies presented at the AACR
meeting.
One-Step Seq™ Method for Library
Construction and Enrichment
Genetron’s One-Step Seq Method is specifically
designed for small to medium size panels and simplifies the
traditional labor intensive library construction/enrichment
experiments to a single mixture of DNA sample to their reagent and
one PCR reaction, minimizing hands-on time and risk of
contamination and reducing the total time for library construction
to 1.5 hours. The operational simplicity of this One-Step Seq
Method makes it easier for hospitals to conduct the testing at a
lower cost, thus yielding better profitability for
hospitals.
Poster 743 presented the research team’s
development of an all-in-one panel for brain cancer based on the
Company’s patented One-Step Seq Method to detect glioma driver gene
mutations and 1p/19q co-deletion, requiring less biopsy and highly
consistent with current technologies such as qPCR and
FISH[1].
Methylation of the MGMT gene promoter is a
biomarker for increased sensitivity to alkylating agent-based
chemotherapy. Poster 3186 presented how the team combined bisulfite
conversion with amplicon sequencing of MGMT gene promoter based on
One-Step Seq method to analyze MGMT promoter methylation status,
the results of which were 94.4% consistent with the gold standard
results[2].
New methodology for the discovery of
novel gene fusion
Compared to single nucleotide polymorphism
(SNPs), it is technically more challenging to detect gene fusions,
in particular, novel unknown fusions. Poster 4149 presented the
research team’s development of an RNA-Capseq panel targeting 395
cancer genes to detect gene fusions. Lung cancer cell lines or
hematological tumors with known fusion genes and the FFPE samples
from 10 patients with unknown types of sarcoma were assessed.
Compared with lncRNA-seq, the RNA-Capseq panel could pinpoint
fusions with a relatively small amount of data, which makes it more
affordable and accessible. Moreover, this method can identify
fusions in cases of low tumor purity or poor RNA quality. Compared
to FISH and RT-PCR, the RNA-Capseq panel can detect more fusion
genes at one time, and also discover novel fusion subtypes[3].
Application of Liquid Biopsy
Low-Frequency Mutation Detection Technology in clinical
investigations
Genetron Health has launched several liquid
biopsy-based tests for cancer diagnosis, early detection, and
monitoring.
Poster 1991 presented a collaborative clinical
study of neoadjuvant chemotherapy (NAC) treatment selection, in
which a cohort of 25 patients with Stage II/III gastric
adenocarcinoma after surgical treatment were enrolled. The research
analyzed the mutation profiles of 50 plasma samples collected from
the patients using its 179 cancer-related gene panel. Copy number
instability (CNI) scores of ctDNA were calculated to reflect
chromosome instability in ctDNA. The results indicated CNI score of
pre- neoadjuvant chemotherapy (NAC) ctDNA is a potential biomarker
of response and prognosis to NAC in gastric cancer patients before
NAC treatment[4].
Leptomeningeal metastases (LM), associated with
poor survival, were much more frequently detected in NSCLC patients
harboring EGFR mutations. Though EGFR-TKIs therapy significantly
increased overall survival, many patients inevitably develop
acquired resistance. Poster 723 presented a study enrolling 31 lung
adenocarcinoma patients harboring EGFR mutations, who had received
at least 6 months of EGFR-TKIs treatment before the diagnosis of
LM. The research collected 10 ml of CSF and matched 10 ml
peripheral blood. The results suggested that, during EGFR-TKIs
treatment, the acquired resistance mutations in the LM for NSCLC
patients were independent from those in extracranial
lesions[5].
Currently, ureteroscopy is commonly used in
pathological tests before surgery. However, in addition to the
trauma and infection risks attached to ureteroscopy, the
possibility of exudation and adhesion of surrounding tissues
significantly increased after the process. Hypertension in the
cavity may cause tumor spread, and the use of ureteroscopy and
biopsy may cause the recurrence of bladder tumors after surgery.
The poster 2293 presented a study where urine from 150 hematuria
patients with upper tract urinary disease and 100 healthy people
were assessed. The liquid biopsy assay tested demonstrated a
sensitivity of 94% and a specificity of 96% in cancer detection[6].
Meanwhile, poster 2296 presented a study that assessed urine from
109 hematuria patients with upper tract urinary disease, in which
the liquid biopsy assay demonstrated a sensitivity of 83.5%, a
specificity of 90%, NPV of 67.5%, and PPV of 95.7% of detection of
cancers[7]. The urinary assay’s high sensitivity, high specificity,
and non-invasiveness make it a potential clinical alternative to
ureteroscopy.
Reference[1] Min Shi, Sumin
Geng, et al. An amplicon sequencing based all-in-one genetic
testing panel for molecular classification and guiding
individualized treatment of brain cancer. Poster 743 presented at
AACR Virtual Annual Meeting II, June 22-24, 2020.[2] Yukun Zhang,
Min Shi, et al. Methylation MGMT gene promoter analysis based on a
high throughput method combines bisulfite conversion with amplicon
sequencing. Poster 3186 presented at AACR Virtual Annual Meeting
II, June 22-24, 2020.[3] Gu Jin, Chunyang Wang, et al. Targeted
RNA-Capseq provides new insight into clinical fusion detection.
Poster 4149 presented at AACR Virtual Annual Meeting II, June
22-24, 2020.[4] Yongning Jia, Honglin Zhu, et al. Chromosomal
Instability of Circulating tumor DNA Predicts Response to
Neoadjuvant Chemotherapy In Gastric Cancer. Poster 1991 presented
at AACR Virtual Annual Meeting II, June 22-24, 2020.[5] Xi Wu,
Puyuan Xing, et al. Genetic profiling of cerebrospinal fluid cfDNA
from NSCLC patients with leptomeningeal metastases reveals
EGFR-TKIs resistant mutations independent of extracranial lesions
(cases series). Poster 723 presented at AACR Virtual Annual Meeting
II, June 22-24, 2020. [6] Yansheng Xu, Hongzhao Li, et al. A
Urine-based liquid biopsy Method for Detection of upper tract
urinary carcinoma. Poster 2293 presented at AACR Virtual Annual
Meeting II, June 22-24, 2020.[7] Hu Qu, Yu Zeng, et al. A
Multicenter, Prospective Evaluation of Urine-Based ctDNA Assay for
Urinary Cancers Diagnosis. Poster 2296 presented at AACR Virtual
Annual Meeting II, June 22-24, 2020.
About Genetron HealthGenetron
Holdings Limited (“Genetron Health”, Nasdaq: GTH) is a
leading precision oncology platform company in China that
specializes in cancer molecular profiling and harnesses advanced
technologies in molecular biology and data science to transform
cancer treatment. The Company has developed a comprehensive product
and service portfolio that cover the full-cycle of cancer care from
early screening, to diagnosis and treatment recommendations, to
continuous monitoring and continuous care.
Forward-looking StatementsThis
press release contains forward-looking statements within the
meaning of federal securities laws, including statements regarding
the potential benefits and advantages of Genetron Health’s One-Step
Seq™ Method, which involve risks and uncertainties that could cause
the actual results to differ materially from the anticipated
results and expectations expressed in these forward-looking
statements. These statements are made under the "safe harbor"
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Such risks and uncertainties include those discussed under
the caption “Risk Factors” in Genetron Health’s filings with the
Securities and Exchange Commission. These forward-looking
statements are based on current expectations, forecasts,
assumptions and information available to Genetron Health as of the
date hereof, and actual outcomes and results could differ
materially from these statements due to a number of factors, and
Genetron Health disclaims any obligation to update any
forward-looking statements provided to reflect any change in its
expectations or any change in events, conditions, or circumstances
on which any such statement is based, except as required by law.
These forward-looking statements should not be relied upon as
representing Genetron Health’s views as of any date subsequent to
the date of this press release. Investors are urged not to rely on
any forward-looking statement in reaching any conclusion or making
any investment decision about any securities of Genetron
Health.
Investor Relations Contact:Stephanie
CarringtonWestwicke, an ICR
CompanyStephanie.Carrington@westwicke.comOffice: +1 (646)
277-1282
Asia:Bill ZimaICR, Inc.Email:
bill.zima@icrinc.comir@genetronhealth.com
Media Relations Contact:Edmond LococoICR, Inc.
Edmond.Lococo@icrinc.comMobile: +86
138-1079-1408pr@genetronhealth.com
Genetron (NASDAQ:GTH)
Historical Stock Chart
From May 2024 to Jun 2024
Genetron (NASDAQ:GTH)
Historical Stock Chart
From Jun 2023 to Jun 2024